Skip to main content
SpringerLink
Log in

DTG-based first-line therapy appears to be cost effective in Ethiopia

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Belay YB, et al. Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia PharmacoEconomics-Open : 17 Jun 2021. Available from: URL: https://doi.org/10.1007/s41669-021-00275-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DTG-based first-line therapy appears to be cost effective in Ethiopia. PharmacoEcon Outcomes News 881, 11 (2021). https://doi.org/10.1007/s40274-021-7807-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7807-8

Search

Navigation